How connecting the data dots can lead to better development and clinical trals. 

Oral solid dosage, HPAPIs, OSD development, OSD formulations, poorly soluble drugs, fixed-dose combinations, controlled release

Experts look at trends in antibody drug development, including the growing popularity of new modalities.

AI is set to be a key disruptor in the pharma industry. Here are two perspectives on how it could change drug development.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.

Doing more to ease the challenges of antibody drug conjugate manufacturing.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

How can you ensure your gene therapy research won’t be slowed down by synthesis problems?